Magle Chemoswed Holding AB (publ) (STO:MAGLE)

Market Cap	412.99M
Revenue (ttm)	292.32M
Net Income (ttm)	-20.16M
Shares Out	20.65M
EPS (ttm)	-1.14
PE Ratio	n/a
Forward PE	80.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,006
Average Volume	1,464
Open	20.40
Previous Close	20.40
Day's Range	20.00 - 20.40
52-Week Range	17.10 - 38.65
Beta	0.45
RSI	49.16
Earnings Date	Oct 31, 2025

About STO:MAGLE

Magle Chemoswed Holding AB (publ), together with its subsidiaries, engages in research and development of pharmaceutical and medical device products in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; and benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson’s disease. The company also offers EmboCept S, a microsphere-based medical dev...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1944
• Employees: 147
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: MAGLE

Financial Performance

In 2024, STO:MAGLE's revenue was 240.57 million, an increase of 40.27% compared to the previous year's 171.50 million. Earnings were 11.94 million, a decrease of -1.91%.